FDA approves nerve-stimulation wearable as first device for adolescent IBS pain

FDA
Similar versions of the nerve-stimulation device have been authorized to reduce the symptoms of opioid withdrawal as well as for use in acupuncture. (Andrew Harnik, Associated Press)

The FDA has approved the first medical device to help reduce abdominal pain in adolescents with irritable bowel syndrome (IBS) through the use of nerve stimulation.

The IB-Stim non-surgical prescription device, developed by Innovative Health Solutions, is designed for patients between 11 and 18 years old. Placed behind the ear, the small, battery-powered device continuously emits mild electrical pulses that target certain branches and bundles of cranial nerves. After five days, the device is replaced.

According to the agency, patients can use the device for up to three consecutive weeks to help reduce functional abdominal pain associated with IBS, alongside other therapies for the syndrome.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

RELATED: FDA OKs behind-the-ear device for opioid withdrawal

Though the FDA reviewed and granted the IB-Stim a 510(k) clearance through its de novo product review pathway, the agency had previously authorized similar versions of the device. In 2017, the agency approved the NSS-2 Bridge device to reduce the symptoms of opioid withdrawal, and the first such approval was in 2014 as the Electro Auricular Device for use in acupuncture.

In a clinical study, 50 adolescent participants with IBS were randomized against a sham treatment. Those who received the device therapy saw greater improvements compared to baseline pain scores after three weeks in measurements of frequency, severity and duration.

Additionally, 52% of treated patients saw at least a 30% drop in their usual levels of pain over the same time period, while 59% reported at least a 30% drop in their worst levels of pain.

That outpaced the 30% and 26% of patients who reached the same levels while receiving the placebo treatment in their usual and worst pain scores, respectively.

Suggested Articles

The supermarket chain received an emergency authorization for its own home collection kit for COVID-19 testing, which includes a telehealth consult.

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.